Braveheart Bio reportedly pricing IPO above marketing range

Investing.com -- Braveheart Bio Inc. plans to price its initial public offering above the marketed range on Wednesday, Bloomberg reported Wednesday.

The cardiovascular disease specialist's offering has received more than ten times the number of subscriptions, with strong interest from mutual funds and healthcare-focused investors during one-on-one meetings, according to the report.

The San Francisco-based company seeks to raise $318.8 million through the IPO by selling 18.8 million shares at a price between $15 and $17 per share. The company targets a valuation of up to $1.2 billion.

Shares are scheduled to start trading on the Nasdaq Global Market on Thursday under the ticker symbol BRVE.

Goldman Sachs Group Inc., Jefferies Financial Group Inc., Toronto-Dominion Bank, Stifel Financial Corp., and Cantor Fitzgerald are managing the offering.

You May Also Be Interested In

• Attovia Therapeutics now indicated to open at $24, far above IPO price of $17
• Find Broadway Shows For the Whole Family on Broadway.com
• Cantor Fitzgerald Reiterates Overweight Rating on SpaceX (SPCX)